Neuromyelitis Optica Spectrum Disorder (NMOSD) Panel, CSF; test site SJH

Anti-MOG; MOG Antibodies; Neuromyelitis Optica (NMO) Antibodies; Anti-NMO; Anti-Aquaporin 4

Aquaporin 4 Antibodies; Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)

CSF

Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbour MOG antibodies. Patients very rarely harbour both antibodies.